Rohtak News Magazine

Alzheimer’s Disease Pipeline Analysis: 100+ Companies are Working to Improve the Treatment Space | DelveInsight

 Breaking News
  • No posts were found

Alzheimer’s Disease Pipeline Analysis: 100+ Companies are Working to Improve the Treatment Space | DelveInsight

November 09
18:28 2022
Alzheimer’s Disease Pipeline Analysis: 100+ Companies are Working to Improve the Treatment Space | DelveInsight

DelveInsight’s, “Alzheimer’s Disease Pipeline Insights, 2022,” report provides comprehensive insights about 100+ companies and 100+ pipeline drugs in Alzheimer’s Disease (AD) pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

 

Key takeaways from the Alzheimer’s Disease Pipeline Insight Report

  • DelveInsight’s Alzheimer’s Disease Pipeline report depicts a robust space with 100+ active players working to develop 100+ pipeline therapies for Alzheimer’s Disease.
  • The leading Alzheimer’s Disease Companies such as Eisai, Biogen, Changchun Huayang High-tech Co. Ltd., Hoffmann-La Roche, vTv Therapeutics, AZTherapies, Cerecin, Neurotrope, Lyndra, AC Immune, INmune Bio, Cassava Sciences, EIP Pharma, Neuraly, AB Science, Cortexyme, Anavex Life Sciences, Athira Pharma, Time Therapeutics, Prilenia Therapeutics, Denali Therapeutics Inc., and others are developing potential drug candidates to boost the Alzheimer’s Disease treatment scenario.
  • This segment of the Alzheimer’s Disease (AD) report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

 

Get an overview of the pipeline landscape @ Alzheimer’s Disease Clinical Trials Analysis

 

Alzheimer’s Disease Overview

Alzheimer’s Disease (AD) is a slowly progressive brain disease that begins many years before symptoms emerge. It is the most common cause of dementia, accounting for an estimated 60% to 80% of cases. The hallmark pathologies of Alzheimer’s disease are the accumulation of the protein fragment beta‐amyloid (plaques) outside neurons in the brain and twisted strands of the protein tau (tangles) inside neurons. These changes are accompanied by the death of neurons and damage to brain tissue. On the basis of severity, this degenerative disease can be classified as mild, moderate, and severe.

 

Recent Breakthroughs of Alzheimer’s Disease Treatment Landscape

  • In February 2021, NeurMedix announced that it had received authorization from the U.S. Food and Drug Administration’s (FDA) Office of Neuroscience, Division of Neurology I, to initiate a pivotal phase 3 clinical trial in Alzheimer’s Disease with its lead clinical drug candidate, NE3107.
  • In December 2019, BioArctic declared the initiation of a research deal with Eisai to investigate further the unique profile of the investigational drug candidate BAN2401.
  • In June 2020, Eli Lilly and Company initiated TRAILBLAZER-ALZ 2, a Phase III clinical study of Donanemab for the treatment of Alzheimer Disease. The study is expected to be completed by December 2023, with an estimated enrollment of 1500 participants.

 

For further information, refer to the detailed report @ Alzheimer’s Disease Pipeline Therapeutics

 

Alzheimer’s Disease Emerging Drugs

  • BAN2401: Eisai
  • Gantenerumab: Hoffmann-La Roche

 

DelveInsight’s Alzheimer’s Disease Pipeline Report covers around 100+ products under different phases of clinical development like

  • Late stage products (Phase III)
  • Mid-stage products (Phase II)
  • Early-stage product (Phase I) along with the details of
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates
  • Route of Administration

 

Dive deep into rich insights for drugs for Alzheimer’s Disease treatment, visit @ New Drug for Alzheimer’s Disease Treatment

 

Scope of the Alzheimer’s Disease Pipeline Report

  • Coverage- Global
  • Alzheimer’s Disease Assessment by Product Type
  • Alzheimer’s Disease Assessment by Stage and Product Type
  • Alzheimer’s Disease Assessment by Route of Administration
  • Alzheimer’s Disease Assessment by Stage and Route of Administration
  • Alzheimer’s Disease Assessment by Molecule Type
  • Alzheimer’s Disease Assessment by Stage and Molecule Type
  • Alzheimer’s Disease Companies: Eisai, Biogen, Changchun Huayang High-tech Co. Ltd., Hoffmann-La Roche, vTv Therapeutics, AZTherapies, Cerecin, Neurotrope, Lyndra, AC Immune, INmune Bio, Cassava Sciences, EIP Pharma, Neuraly, AB Science, Cortexyme, Anavex Life Sciences, Athira Pharma, Time Therapeutics, Prilenia Therapeutics, Denali Therapeutics Inc., and many others.  

 

Table of Content

  1. Introduction
  2. Executive Summary
  3. Alzheimer’s Disease (AD): Overview
  4. Pipeline Therapeutics
  5. Therapeutic Assessment
  6. Alzheimer’s Disease (AD) – DelveInsight’s Analytical Perspective
  7. In-depth Commercial Assessment
  8. Alzheimer’s Disease (AD) Collaboration Deals
  9. Late Stage Products (Phase III)
  10. BAN2401: Eisai
  11. Mid Stage Products (Phase II)
  12. Bryostatin-1: Neurotrope
  13. Early Stage Products (Phase I)
  14. INB03 – INmune Bio
  15. Pre-clinical and Discovery Stage Products
  16. AZT-211: AZTherapies
  17. Inactive Products
  18. Alzheimer’s Disease (AD) Key Companies
  19. Alzheimer’s Disease (AD) Key Products
  20. Alzheimer’s Disease (AD)- Unmet Needs
  21. Alzheimer’s Disease (AD)- Market Drivers and Barriers
  22. Alzheimer’s Disease (AD)- Future Perspectives and Conclusion
  23. Alzheimer’s Disease (AD) Analyst Views
  24. Alzheimer’s Disease (AD) Key Companies
  25. Appendix

 

For any query related to the Alzheimer’s Disease Pipeline Report @ Alzheimer’s Disease Companies

 

About Us

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

Related Articles